Bad Blood
★★★★★ 4.5 (238 ratings)
$14.99
Buy on Amazon View on Apple BooksPrefer it in print? See every format on Amazon →
Price on Apple Books. Amazon’s price may differ.
- Also as an audiobook
- Bad Blood: Secrets and Lies in a Silicon Valley Startup (Unabridged)
- Published
In other languages: Bad Blood · Portuguese Bad Blood: Secrets and Lies in a Silicon Valley Startup (Unabridged) · Dutch Ont blod : hemligheter och lögner i Silicon Valley · German Ont blod : hemligheter och lögner i Silicon Valley · Swedish
On the charts
| Position | Best | Days | |
|---|---|---|---|
| Small Business & Entrepreneurship | #7 ▼6 | #1 | 6 |
| Business & Personal Finance | #90 ▼76 | #32 | 5 |
Rank in the last 30 days · #1–#90 · Position 90
For authors: put this badge on your website
Copy this code into your website or blog:
Description
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.